Evidence map›Paper›PMID 32598517›Full record

ArticleFEBS open bio2020

Downregulation of miRNA-126-3p is associated with progression of and poor prognosis for lung squamous cell carcinoma.

Shang-Wei Chen, Hui-Ping Lu, Gang Chen, Jie Yang, Wan-Ying Huang, Xiang-Ming Wang, Shu-Ping Huang, Li Gao, Jun Liu, Zong-Wang Fu and 10 more

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Shang-Wei ChenDepartment of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Hui-Ping LuDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jie YangDepartment of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, China.
Wan-Ying HuangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xiang-Ming WangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shu-Ping HuangDepartment of Medical Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Li GaoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jun LiuDepartment of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zong-Wang FuDepartment of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Peng ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Gao-Qiang ZhaiDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jiao LuoDepartment of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xiao-Jiao LiDepartment of PET/CT, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhi-Guang HuangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zu-Yun LiDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ting-Qing GanDepartment of Medical Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Da-Ping YangDepartment of Pathology, Guigang People's Hospital of Guangxi/the Eighth Affiliated Hospital of Guangxi Medical University, Guigang, China.
Wei-Jia MoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Hua-Fu ZhouDepartment of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China.ORCID 0000-0002-2267-3164
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung squamous cell carcinoma (LUSC) is the main pathological type of pulmonary malignant tumors; at present, less than 10% of patients with advanced metastatic LUSC live for more than 5 years. We previously reported that low expression of miRNA-126-3p is associated with the occurrence and progression of lung adenocarcinoma (LUAD). Here, we examined expression of miRNA-126-3p in 23 samples from patients with LUSCs and 23 normal control specimens by quantitative real-time PCR (RT-qPCR). Associations between miRNA-126-3p expression and clinical features were studied from materials derived from Gene Expression Omnibus (GEO) chips and The Cancer Genome Atlas (TCGA) database. Twelve online platforms were used to identify candidate target genes of miRNA-126-3p. Further analyses of the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and protein-protein interaction (PPI) network were performed on the target genes. GEO microarray analysis, TCGA data mining, RT-qPCR, and integration analysis consistently reported low expression of miRNA-126-3p in LUSC. A total of 42 genes were identified as potential target genes of miRNA-126-3p from online platforms, GEO microarrays, and the TCGA database. GO and KEGG analyses demonstrated that the target genes are involved in several biological processes that promote the progression of LUSC. SOX2, E2F2, and E2F3 were selected as hub genes from the PPI network for further analysis. In summary, our results suggest that the low expression of miRNA-126-3p may play a role in promoting the development of LUSC and miRNA-126-3p may be a biomarker for LUSC early diagnosis and prognosis.

Indexed as

Down-RegulationCarcinoma, Squamous CellFemaleHumansLung NeoplasmsMaleMicroRNAsMiddle AgedMicroRNAsMIRN126 microRNA, humanlung squamous cell carcinomaMiRNA-126-3pRT-qPCRtarget genesTCGA

Identifiers

PMID32598517
PMCPMC7396450
OpenAlexW3040190918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.